GlassScriptPhysician profile
Joshua C Oderanti
NPI 1114441102
$2,386.95
in general payments reported to CMS, 2019-2025
19 companies · $1,311 in 2025
The $1,311 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $85.55 · 2022: $12.93 · 2023: $317 · 2024: $660 · 2025: $1,311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,288.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $553.47 | 2024-2025 | Darzalex, Tecvayli, Rybrevant |
| Glaxosmithkline, LLC. | $291.68 | 2023-2025 | Nucala, Jemperli, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $262.26 | 2021-2024 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Pharmacosmos Therapeutics INC. | $240.75 | 2025 | Monoferric |
| E.R. Squibb & Sons, L.L.C. | $237.78 | 2024-2025 | Reblozyl, Opdivo |
| Puma Biotechnology, INC. | $197.17 | 2023-2024 | |
| Geron Corporation | $113.84 | 2025 | Rytelo |
| Neurocrine Biosciences, INC. | $111.75 | 2024 | Ingrezza |
| Gilead Sciences, INC. | $104.78 | 2023 | |
| Lilly USA, LLC | $81.04 | 2025 | |
| Vanda Pharmaceuticals INC. | $55.32 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.19 | 2024 | |
| Genentech USA, INC. | $18.41 | 2025 | Venclexta |
| Lundbeck LLC | $17.97 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $17.66 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $17.50 | 2025 | Qinlock, Romvimza |
| Abbvie INC. | $16.86 | 2025 | |
| Eisai INC. | $15.59 | 2025 | |
| Indivior INC. | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Oderanti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.